Tatva Chintan Pharma Chem Q1 FY27: net profit up 140% to ₹15.98 crore, revenue up 43%

What happened

Tatva Chintan Pharma Chem (TATVA) told the exchanges on 19 October 2026 at 03:55 PM that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹167 crore (+42.9% year on year), net profit of ₹15.98 crore (+140.3%), earnings per share of ₹6.83.

Company snapshot

Tatva Chintan Pharma Chem is a small-cap company, with a market value of about ₹4,547 crore.

The stock last traded at ₹1,944, against a 52-week range of ₹1,044.1–₹2,008.7 (3.2% below the high).

Before this filing the shares had moved +13.7% over the month and +15.4% over three months. Average daily turnover over the last 20 sessions was about ₹16.93 crore.

Promoters held 72.02% at the end of Q1 FY27. Foreign institutions owned 3.93% and domestic institutions 3.11%.

What history shows

BCEIE's records show 1 previous results filing from the company since May 2026.

Market-wide, 9,607 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.
• 19 October 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

• Tatva Chintan Pharma Chem Ltd. near 52-week high streak — Univest, 7 Oct 2026
• Tatva Chintan Pharma Chem Ltd. Share Price Live Today — CNBC TV18, 16 Oct 2026
• Tatva Chintan (NSE:TATVA) Q2FY27 Earnings Call Date — Kalkine India, 13 Oct 2026
• Tatva Chintan Pharma Chem Ltd. (TATVA) Share Price Hits Fresh 52-Week High at Rs 1,898.25 — Univest, 7 Oct 2026
• Tatva Chintan Pharma Chem 52 Week High Streak, Valuation — Univest, 8 Oct 2026

Source

• Exchange filing (PDF)